Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.

Darras BT, Farrar MA, Mercuri E, Finkel RS, Foster R, Hughes SG, Bhan I, Farwell W, Gheuens S.

CNS Drugs. 2019 Aug 16. doi: 10.1007/s40263-019-00656-w. [Epub ahead of print]

PMID:
31420846
2.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E.

N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944.

PMID:
31390500
3.

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.

Alexander VJ, Xia S, Hurh E, Hughes SG, O'Dea L, Geary RS, Witztum JL, Tsimikas S.

Eur Heart J. 2019 Sep 1;40(33):2785-2796. doi: 10.1093/eurheartj/ehz209.

4.

IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.

Ferrone JD, Bhattacharjee G, Revenko AS, Zanardi TA, Warren MS, Derosier FJ, Viney NJ, Pham NC, Kaeser GE, Baker BF, Schneider E, Hughes SG, Monia BP, MacLeod AR.

Nucleic Acid Ther. 2019 Apr;29(2):82-91. doi: 10.1089/nat.2018.0754. Epub 2019 Feb 28.

5.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

6.

Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy.

Pinto MV, Dyck PJB, Gove LE, McCauley BM, Ackermann EJ, Hughes SG, Waddington-Cruz M, Dyck PJ.

J Neurol Sci. 2018 Nov 15;394:78-83. doi: 10.1016/j.jns.2018.08.031. Epub 2018 Aug 30.

PMID:
30219500
7.

Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.

Waddington-Cruz M, Ackermann EJ, Polydefkis M, Heitner SB, Dyck PJ, Barroso FA, Wang AK, Berk JL, Dyck PJB, Monia BP, Hughes SG, Tai L, Jesse Kwoh T, Jung SW, Coelho T, Benson MD, Gertz MA.

Amyloid. 2018 Sep;25(3):180-188. doi: 10.1080/13506129.2018.1503593. Epub 2018 Aug 31.

PMID:
30169969
8.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

9.

The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans.

Crooke ST, Baker BF, Pham NC, Hughes SG, Kwoh TJ, Cai D, Tsimikas S, Geary RS, Bhanot S.

Nucleic Acid Ther. 2018 Feb;28(1):10-22. doi: 10.1089/nat.2017.0693. Epub 2017 Nov 29.

10.

Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.

Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S.

J Clin Lipidol. 2018 Jan - Feb;12(1):122-129.e2. doi: 10.1016/j.jacl.2017.10.024. Epub 2017 Nov 2.

PMID:
29174389
11.
12.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

13.

The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.

Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, McEvoy BW, Cheng W, Hughes SG, Bhanot S, Geary RS.

Nucleic Acid Ther. 2017 Jun;27(3):121-129. doi: 10.1089/nat.2016.0650. Epub 2017 Feb 1.

14.

Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, Ruzhansky K, Cortese A, Brannagan TH 3rd, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Conceição I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ.

Muscle Nerve. 2017 Nov;56(5):901-911. doi: 10.1002/mus.25563. Epub 2017 Apr 7.

15.

Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.

Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, Kim TW, Jesse Kwoh T, Matson J, Norris D, Yu R, Watt A, Monia BP.

Amyloid. 2016 Sep;23(3):148-157. Epub 2016 Jun 29.

PMID:
27355239
16.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
17.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM.

Diabetes Care. 2016 Aug;39(8):1408-15. doi: 10.2337/dc16-0126. Epub 2016 Jun 6.

PMID:
27271183
18.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR.

Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272.

19.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ.

N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283.

20.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
21.
22.

The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up.

Sugihara C, Freemantle N, Hughes SG, Furniss S, Sulke N.

J Interv Card Electrophysiol. 2015 Jun;43(1):91-8. doi: 10.1007/s10840-015-9986-3. Epub 2015 Feb 25.

PMID:
25711952
23.

Targeting APOC3 in the familial chylomicronemia syndrome.

Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL.

N Engl J Med. 2014 Dec 4;371(23):2200-6. doi: 10.1056/NEJMoa1400284.

24.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators.

Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.

25.

Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.

Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Jimenez CR, Johnson MH, Killestein J, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Deisenhammer F, Giovannoni G, Hemmer B.

Mult Scler Int. 2011;2011:246412. doi: 10.1155/2011/246412. Epub 2011 Jul 18. Retraction in: Multiple Sclerosis International. Mult Scler Int. 2016;2016:8304273.

26.

Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'.

Teunissen CE, Tumani HT, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Hemmer B, Deisenhammer F, Giovannoni G.

Mult Scler. 2010 Feb;16(2):129-32. doi: 10.1177/1352458509356368. Epub 2009 Dec 30. No abstract available.

PMID:
20042453
27.

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F.

Neurology. 2009 Dec 1;73(22):1914-22. doi: 10.1212/WNL.0b013e3181c47cc2.

28.

Postscript: some concluding observations and speculations.

Hughes SG, Garland JM.

Symp Soc Exp Biol. 2000;52:301-4. No abstract available.

PMID:
12090017
29.

Unusual complications following laparoscopic Nissen fundoplication.

Hughes SG, Chekan EG, Ali A, Reintgen KL, Eubanks WS.

Surg Laparosc Endosc Percutan Tech. 1999 Apr;9(2):143-7. Review.

PMID:
11757543
30.

Prescribing for the elderly patient: why do we need to exercise caution?

Hughes SG.

Br J Clin Pharmacol. 1998 Dec;46(6):531-3. No abstract available.

31.

Evolving projection analysis of multicomponent mixtures.

Hughes SG, Wentzell PD.

Talanta. 1995 Oct;42(10):1361-71.

PMID:
18966364
32.

Effects of feeding a high level of D-glucose on liver function in juvenile white sturgeon (Acipenser transmontanus).

Fynn-Aikins K, Hung SS, Hughes SG.

Fish Physiol Biochem. 1993 Dec;12(4):317-25. doi: 10.1007/BF00004416.

PMID:
24202873
33.

The isolation and sequence analysis of two seed-expressed acyl carrier protein genes from Brassica napus.

de Silva J, Loader NM, Jarman C, Windust JH, Hughes SG, Safford R.

Plant Mol Biol. 1990 Apr;14(4):537-48.

PMID:
2102833
34.

Messenger RNA from isolated aleurone cells directs the synthesis of an alpha-galactosidase found in the endosperm during germination of guar (Cyamopsis tetragonaloba) seed.

Hughes SG, Overbeeke N, Robinson S, Pollock K, Smeets FL.

Plant Mol Biol. 1988 Nov;11(6):783-9. doi: 10.1007/BF00019518.

PMID:
24272628
35.

Plastid-localised seed acyl-carrier protein of Brassica napus is encoded by a distinct, nuclear multigene family.

Safford R, Windust JH, Lucas C, De Silva J, James CM, Hellyer A, Smith CG, Slabas AR, Hughes SG.

Eur J Biochem. 1988 Jun 1;174(2):287-95.

36.

Molecular cloning and sequence analysis of complementary DNA encoding rat mammary gland medium-chain S-acyl fatty acid synthetase thio ester hydrolase.

Safford R, de Silva J, Lucas C, Windust JH, Shedden J, James CM, Sidebottom CM, Slabas AR, Tombs MP, Hughes SG.

Biochemistry. 1987 Mar 10;26(5):1358-64.

PMID:
3105579
37.

Effects of psoralen on replicon size and mean rate of DNA synthesis in partially synchronized cells of Pisum sativum L.

Francis D, Davies ND, Bryant JA, Hughes SG, Sibson DR, Fitchett PN.

Exp Cell Res. 1985 Jun;158(2):500-8.

PMID:
4007063
38.

Cloning an Aspergillus nidulans developmental gene by transformation.

Johnstone IL, Hughes SG, Clutterbuck AJ.

EMBO J. 1985 May;4(5):1307-11.

40.

Effect of excess dietary riboflavin on growth of rainbow trout.

Hughes SG.

J Nutr. 1984 Sep;114(9):1660-3.

PMID:
6470823
41.

The life and work of John Howard Mummery.

Hughes SG.

Bull Hist Dent. 1983 Oct;31(2):69-81. No abstract available.

PMID:
6357318
42.

Branched-chain amino acid aminotransferase activity in the tissues of lake trout.

Hughes SG, Rumsey GL, Nesheim MC.

Comp Biochem Physiol B. 1983;76(3):429-31.

PMID:
6641168
43.

Biomicroscopic and histologic pathology of the eye in riboflavin deficient rainbow trout (Salmogairdneri).

Hughes SG, Riis RC, Nickum JG, Rumsey GL.

Cornell Vet. 1981 Jul;71(3):269-79.

44.
45.
47.

Isolation and characterization of two sequence-specific endonucleases from Anabaena variabilis.

Murray K, Hughes SG, Brown JS, Bruce SA.

Biochem J. 1976 Nov;159(2):317-22.

48.

The sensitivity of bacteriophage lambda DNA to restriction endonuclease RII.

Hughes SG.

J Mol Biol. 1975 Nov 5;98(3):645-7. No abstract available.

PMID:
1104876
49.

Plasmid identification using specific endonucleases.

Thompson R, Hughes SG, Broda P.

Mol Gen Genet. 1974;133(2):141-9. No abstract available.

PMID:
4614064
50.

Supplemental Content

Loading ...
Support Center